Table 2. Association between clinical, pathological, molecular and metabolic markers and pCR in the population of ER-positive, HER2-negative breast cancers (categorical variables as count (%) and continuous variables as median(interquartile range)).
| N patients | No pCR | pCR | P† | |
|---|---|---|---|---|
| Total number of patients | 75 | 69 | 6 | |
| Tumor size | 0.66 | |||
| T0-T1-T2 | 27 (36%) | 24 (35%) | 3 (50%) | |
| T3-T4 | 48 (64%) | 45 (65%) | 3 (50%) | |
| Histological Grade | ||||
| Grade-1-2 | 53 (71%) | 53 (77%) | 0 (0%) | 0.0004 |
| Grade-3 | 22 (29%) | 16 (23%) | 6 (100%) | |
| Biological markers | ||||
| ER positivity n(%) | 74 (99%) | 68 (99%) | 6 (100%) | 1 |
| PR positivity n (%) | 39 (52%) | 39 (57%) | 0 (0%) | 0.01 |
| P53 status | ||||
| Mutated | 20 (27%) | 16 (24%) | 4 (67%) | 0.042 |
| Wild type | 54 (73%) | 48 (76%) | 2 (33%) | |
| Proliferation markers | ||||
| Ki67 (IHC) | 18 (7 to 38) | 18 (6 to 37) | 26 (15 to 50) | 0.34 |
| Ki67 (RT-qPCR) | 288 (12 to 2131)* | 304 (12 to 2131)* | 241 (26 to 420)* | 0.31 |
| CDC2 | 70 (8 to 373)* | 70 (8 to 373)* | 67 (17 to 154)* | 0.61 |
| CDC20 | 186 (12 to 899)* | 200 (12 to 899)* | 120 (49 to 576)* | 0.33 |
| KPNA2 | 215 (17 to 6723)* | 227 (20 to 6723)* | 194 (17 to 248)* | 0.15 |
| MYBL2 | 146 (15 to 4131)* | 146 (15 to 4131)* | 150 (23 to 555)* | 0.79 |
| GGI | 153 (104 to 324)* | 153 (106 to 324)* | 143 (57 to 174)* | 0.39 |
| Metabolic markers | ||||
| SUV max tumoral PET1 | 6 (4 to 8) | 6 (4 to 8) | 7 (6 to 10) | 0.34 |
| SUV max tumoral PET2 | 4 (2 to 5) | 4 (2 to 5) | 3 (2 to 5) | 0.35 |
| ΔSUV max tumoral (%) | 34 (22 to 50) | 33 (17 to 48) | 62 (50 to 73) | 0.008 |
†P=P-value for Fisher’s exact test (discrete variables) and Wilcoxon’s rank sum test (continuous variables); values in bold font correspond to values inferior to significant threshold 0.05, indicating significant association.
*Arbitrary Units.